Clinical Trial Detail

NCT ID NCT03455556
Title Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Mayo Clinic
Indications

lung non-small cell carcinoma

Therapies

Anetumab ravtansine + Atezolizumab

Age Groups: adult senior

No variant requirements are available.